Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers
Real-world follow-up data from 465 patients add to evidence from earlier randomized trials.
-
By
-
Kathryn Wighton
-
June 27, 2026
-
Clinical Scorecard: Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers
At a Glance
| Category | Detail |
|---|
| Condition | Symptomatic Obstructive Hypertrophic Cardiomyopathy |
| Key Mechanisms | Selective cardiac-specific myosin inhibitor |
| Target Population | Adults with symptomatic obstructive hypertrophic cardiomyopathy |
| Care Setting | Retrospective analysis of patient-level data across multiple sites |
Key Highlights
- Statistically significant improvements in diastolic function and cardiac remodeling markers at 18 months
- Increased medial e′ velocity from 0.05 m/s to 0.06 m/s
- Decreased average E/e′ ratio from 17.4 to 14.2
- Decreased left ventricular wall thickness (LVWT) from 18.5 mm to 17.6 mm
- No new safety signals reported
Guideline-Based Recommendations
Diagnosis
- Assessment of echocardiographic markers for diagnosis of obstructive hypertrophic cardiomyopathy
Management
- Mavacamten treatment in accordance with US Prescribing Information
Monitoring & Follow-up
- Regular echocardiographic assessments at baseline and follow-up
Risks
- Retrospective, uncontrolled analysis limits interpretation of safety findings
Patient & Prescribing Data
465 patients with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten showed improvements in diastolic function and cardiac remodeling markers
Clinical Best Practices
- Monitor echocardiographic parameters regularly in treated patients
- Consider patient selection and concurrent management in interpreting treatment effects
Related Resources & Content
